Backgrounds: Fascioliasis is a disease of the hepatobiliary system, caused by Fasciola spp that are increasing and threating of public health in the tropic areas (Africa and Asia), including of Central part of Vietnam. WHO estimates that at least 2.4 million people are infected in more than 70 countries worldwide, with several million at risk.No continent is free from fascioliasis, and it is likely that where animal cases are reported, human cases also exist. This study carried out to evaluate several particular clinical aspects in the vulnerable groups with fascioliasis.
Significant headway has been made in controlling malaria. However, two vexing problems remain: currently available treatments are unable to block transmission of the parasite that causes the disease, and the parasite often becomes resistant to drugs. According to a new study led by researchers at ColumbiaUniversityMedicalCenter (CUMC), there is a class of compounds that could address both of these problems.
Chicken odour 'prevents malaria' research in Ethiopia finds;Nigerian biotech firm develops urine test for malaria; Malaria's Magnetic Properties May Pull Treatments Forward; Anti-malaria drug could help fight cancer; Scientists exploit malaria's Achilles' heel.